MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith extract of unaudited financial results of the Company for the quarter ended June 30, 2022 published on August 15, 2022 in the Business Standard (English) and Lakshadeep (Marathi) newspapers. Q1FY23 Quarterly Result Announced for Marksans Pharma Ltd.
Marksans Pharma announced Q1FY23 Result : Operating revenue was Rs. 433.8 cr., growing by +24.3% driven by a strong volume growth in existing products and new launches in the US & UK. US business grew by +25.7%. Pricing erosion in the US continued in the high single digit during the quarter impacting Generic Rx business. UK and Europe grew by +13.7% Gross profit was Rs 218.9 cr, growing by +17.3% YoY with Gross margin at 50.5%. EBITDA was Rs 72.9 cr., declining by 5.8% with EBITDA margin at 16.8%, on account of increase in costs of material, freight costs, and pricing pressure in the US. R&D; spend was at 2% of sales Healthy cash balance of Rs. 339 cr Mark Saldanha, Managing Director of the Company said "We had a strong start to the year, achieving good growth across all our regions. Our existing business, new product approvals, and launches continue to drive the momentum. We have emerged as a prime manufacturer and marketer of private-label store brands of consumer healthcare products in the USA, UK and Australia. This is driven by our commitment to invest in product innovation, newer capacities, and increasing penetration. Looking ahead, we see growing demand in our OTC segment across the regions, and we are well-positioned to take advantage of these opportunities." Result PDF MARKSANS PHARMA LTD. - 524404 - Statement On Deviation Or Variation Of Funds Raised Through Preferential Issue Of Convertible Warrants
Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMDl/162/2019 dated December 24, 2019, we hereby confirm that there is no deviation or variation in the use of funds raised through Preferential Issue of Convertible Warrants from the objects stated in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated 15th June, 2021. Accordingly, a Nil Statement of Deviation, duly reviewed by the Audit Committee of the Company, for the Quarter ended 30th June, 2022 is given in "Annexure A". MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release dated 13th August, 2022 titled Q1FY23 Financial Results MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation Q1FY23 MARKSANS PHARMA LTD. - 524404 - Unaudited Financial Results For The Quarter Ended 30Th June, 2022 And Limited Review Report Thereon
In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results (both Standalone and Consolidated) for the quarter ended 30th June, 2022 which have been approved by the Board of Directors at its meeting held today i.e. 13th August, 2022 along with Limited Review Reports given by statutory auditor of the Company. The meeting commenced at 6:20 p.m. and concluded at 7:40 p.m. MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Please find attached daily report pursuant to Regulation 18 of Buyback Regulations MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Q1FY23 Earnings Call. MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Please find attached daily report pursuant to Regulation 18 of Buyback Regulations MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith Notice of 30th AGM, Book closure and e-voting information published on August 6, 2022 in the Business Standard (English) and Lakshadeep (Marathi) newspapers.